Showing results (91-100 of 198) with videos related to
Sort By:
Pageof 20
Cancer Research|November 25, 2003
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytesSimona Vertuani, Anna De Geer, Victor Levitsky, et al.International Journal of Oncology|February 13, 2009
The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2AAnnica Wilzén, Staffan Nilsson, Rose-Marie Sjöberg, et al.Journal of Medical Virology|March 12, 2003
Identification of a unique BK virus variant in the CNS of a patient with AIDSGunn Eli Kimo Jørgensen, Anna-Lena Hammarin, Gøran Bratt, et al.International Journal of Oncology|December 25, 2010
Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenograftsTzvetomira Philipova, Ninib Baryawno, Wolfgang Hartmann, et al.Ejhaem|January 30, 2026
Systemic Immune Alterations in Paediatric Classical Hodgkin Lymphoma With CCL17 and MCP-4 as Diagnostic and Predictive BiomarkersGustav Hedberg, Qi Chen, Tadepally Lakshmikanth, et al.International Journal of Oncology|February 13, 2003
Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrateIrina Svechnikova, Steven G Gray, Jurgita Kundrotiene, et al.Biochemical and Biophysical Research Communications|July 6, 2011
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell modelsAna-Maria Marino, Anastasios Sofiadis, Ninib Baryawno, et al.BMC Medical Genomics|August 19, 2009
Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genesKaisa Thorell, Annika Bergman, Helena Carén, et al.BMC Genomics|September 9, 2011
Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumorsHanna Kryh, Helena Carén, Jennie Erichsen, et al.International Journal of Oncology|July 14, 2011
MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastomaHanna Kryh, Jonas Abrahamsson, Elsa Jegerås, et al.Pageof 20